Ipsen reports positive limb spasticity drug trial data

Ipsen has announced positive clinical trial data from a new study of Dysport at the recent World Congress for NeuroRehabilitation in Istanbul.

The study data revealed that in adults with upper limb spasticity, treatment with Dysport demonstrated improvement in muscle tone, clinical benefit and passive function, four weeks after the initial injection.

Moreover, the safety profile observed in the study was consistent with the known performance of Dysport. Further findings from the trial will be presented at forthcoming international congresses in the next few months.

Dysport is approved for the treatment of upper limb spasticity in many international markets and was first made available in the UK in 1990. However, it is yet to receive US regulatory approval.

Claude Bertrand, executive vice-president for research and development and chief scientific officer of Ipsen, said: "We are pleased that the first robust set of results from the phase III clinical study was presented by the principal investigator of the study, Professor JM Gracies, at this 
major congress."

This comes after the company recently held a special conference discussing developments in cancer research, attended by leading experts, to mark the 30th anniversary of the Fondation Ipsen.